Zeeshan Ali, Neeta Maheshwary, Uffaq Zara, Siddiqi Ahson, Muhammad Athar Khan.
ALT changes and adverse events of telbivudine in hepatitis-b patients-an experience of 11 patients.
J Ayub Med Coll Abottabad Jan ;27(1):241-2.

Hepatitis-B virus (HBV) infection is a major global health problem. Of the two billion people who have been infected, more than 350 million have chronic hepatitis. It is estimated that 235,000–328,000 people die annually due to liver cirrhosis and hepatocellular carcinoma, we assessed the short term outcomes of treatment with telbivudine in 11 adults aged 14–41 years with HBeAg-positive or HBeAgnegative chronic hepatitis-B (CHB). Treatment of chronic hepatitis-B patients with telbivudine shows 43.1% reduction in serum ALT with no significant adverse effects.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com